MYCN and neoplasm: In 2014, Chipumuro et al. reported that a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), THZ1, was found to disrupt the transcription of MYCN-amplified NB cells selectively, leading to global repression of N-Myc-dependent transcriptional amplification and induction of tumour regression in mice models (Figure 2, Table 2) [105].